Rhenman & Partners Asset Management AB Lowers Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Rhenman & Partners Asset Management AB reduced its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 53.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 100,400 shares of the company’s stock after selling 114,600 […]
More Stories
Vipshop Holdings Limited (NYSE:VIPS) Receives $17.50 Average PT from Analysts
Shares of Vipshop Holdings Limited (NYSE:VIPS – Get Free Report) have earned a consensus rating of “Hold” from the seven...
Crown Castle (NYSE:CCI) and CubeSmart (NYSE:CUBE) Head to Head Review
CubeSmart (NYSE:CUBE – Get Free Report) and Crown Castle (NYSE:CCI – Get Free Report) are both finance companies, but which...
Contrasting Wynn Macau (OTCMKTS:WYNMY) and Civeo (NYSE:CVEO)
Civeo (NYSE:CVEO – Get Free Report) and Wynn Macau (OTCMKTS:WYNMY – Get Free Report) are both consumer discretionary companies, but...
Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) PT at $31.67
Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) have earned a consensus rating of “Buy” from the seven...
Reviewing HUYA (NYSE:HUYA) & Nexxen International (NASDAQ:NEXN)
HUYA (NYSE:HUYA – Get Free Report) and Nexxen International (NASDAQ:NEXN – Get Free Report) are both small-cap computer and technology...
Brokerages Set indie Semiconductor, Inc. (NASDAQ:INDI) Price Target at $8.92
indie Semiconductor, Inc. (NASDAQ:INDI – Get Free Report) has been assigned an average rating of “Buy” from the six research...